Blog
RSS FeedPosted by Michael Wonder on 26 Oct 2018
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
26 October 2018 - NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not ...
Posted by Michael Wonder on 20 Oct 2018
Some European countries decide to cover cancer drugs much faster than others
19 October 2018 - Some European countries take more than twice as long as others to decide whether to provide ...
Posted by Michael Wonder on 19 Oct 2018
NICE rejects Lilly’s breast cancer drug Verzenios
19 October 2018 - As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast ...
Posted by Michael Wonder on 18 Oct 2018
NHS green light for Novartis skin cancer combo
18 October 2018 - The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available ...
Posted by Michael Wonder on 08 Oct 2018
NICE expands backing for Pfizer’s Mylotarg
8 October 2018 - NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with ...
Posted by Michael Wonder on 04 Oct 2018
NICE publishes draft guidance for idelalisib
4 October 2018 - The Department of Health and Social Care has asked the NICE to produce guidance on using idelalisib ...
Posted by Michael Wonder on 03 Oct 2018
Preliminary NICE ‘no’ for Takeda’s Alunbrig
3 October 2018 - Draft guidelines from the NICE do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig. ...
Posted by Michael Wonder on 19 Sep 2018
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
19 September 2018 - The National Institute for Health and Care Excellence has turned down NHS funding for use of ...
Posted by Michael Wonder on 19 Sep 2018
NICE encourages further discussions on Kymriah for adult lymphoma
19 September 2018 - CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft ...
Posted by Michael Wonder on 17 Sep 2018
Targeted treatment for melanoma to be free on NHS
17 Septembre 2018 - Hundreds of patients with a type of aggressive skin cancer will be offered a targeted therapy ...
Posted by Michael Wonder on 17 Sep 2018
Patients with high-risk skin cancer have new treatment option
17 September 2018 - Hundreds of patients with a type of advanced skin cancer are set to benefit from a new ...
Posted by Michael Wonder on 13 Sep 2018
DoH moves to ensure equal access to cancer drugs in Northern Ireland
13 September 2018 - The Department of Health in Northern Ireland has unveiled plans to boost access to innovative new ...
Posted by Michael Wonder on 10 Sep 2018
NICE turns down Opdivo for adjuvant melanoma therapy
10 September 2018 - BMS drug currently only licensed treatment in this setting. ...
Posted by Michael Wonder on 05 Sep 2018
Deal for NHS to offer exciting new child cancer therapy
5 September 2018 - A deal has been struck to let the NHS offer children an expensive new cancer therapy ...
Posted by Michael Wonder on 04 Sep 2018
Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs
4 September 2018 - NICE quibbled with Merck's methodology for demonstrating the cost effectiveness of Keytruda in treating Hodgkin lymphoma patients ...